Drug Profile
Anti-interleukin-1-beta polyclonal antibody
Alternative Names: Anti-IL1-beta polyclonal antibody; IL1-beta-neutralising antibodyLatest Information Update: 10 Aug 1998
Price :
$50
*
At a glance
- Originator R&D Systems
- Class Polyclonal antibodies
- Mechanism of Action Interleukin 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Transplant rejection
Most Recent Events
- 10 Aug 1998 No-Development-Reported for Transplant rejection in USA (Unknown route)
- 06 Mar 1996 Preclinical development for Transplant rejection in USA (Unknown route)